| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6747019 | TEVA WOMENS | Low dose estrogen interrupted hormone replacement therapy |
Mar, 2020
(4 years ago) | |
| US7320970 | TEVA WOMENS | Low dose estrogen interrupted hormone replacement therapy |
Mar, 2020
(4 years ago) | |
Prefest is owned by Teva Womens.
Prefest contains Estradiol; Norgestimate.
Prefest has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Prefest are:
- US6747019
- US7320970
Prefest was authorised for market use on 22 October, 1999.
Prefest is available in tablet;oral dosage forms.
Prefest can be used as prefest is indicated in women who have a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause; treatment of vulvar and vaginal atrophy; prevention of osteoporosis, hormone replacement.
The generics of Prefest are possible to be released after 30 March, 2020.
Drugs and Companies using ESTRADIOL; NORGESTIMATE ingredient
Market Authorisation Date: 22 October, 1999
Treatment: Hormone replacement; Prefest is indicated in women who have a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause; Treatment of vulvar and vaginal atrophy; Prev...
Dosage: TABLET;ORAL
PREFEST family patents
